Glycosylation of plasma IgG in colorectal cancer prognosis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Theodoratou, Evropi ^a,b   Thaçi, Kujtim ^c   Agakov, Felix ^d   Timofeeva, Maria N ^b   Stambuk, Jerko ^c   Pueìc Bakovic, Maja ^c   Vuèkovic, Frano ^c   Orchard, Peter ^d   Agakova, Anna ^d   Din, Farhat V N ^b   Brown, Ewan ^e   Rudd, Pauline M ^f   Farrington, Susan M ^b   Dunlop, Malcolm G ^b   Campbell, Harry ^a,b   Lauc, Gordan ^c,g  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^d PHARMATICS LIMITED   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f National Institute for Bioprocessing Research and Training   (Ireland)

^g UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED IGG; IMMUNOGLOBULIN G; TUMOR MARKER;

AGED; ALGORITHM; AREA UNDER THE CURVE; BLOOD; CANCER STAGING; COLORECTAL TUMOR; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL ANALYSIS;

AGED; ALGORITHMS; AREA UNDER CURVE; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84974846031     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28098     Document Type: Article

References (52)

1. National Institute for Health and Clinical Excellence. Colorectal cancer. The diagnosis and management of colorectal cancer (2011).
2. Kim, H. J., Yu, M. H., Kim, H., Byun, J., Lee, C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 41, 685-692 (2008).
3. Dennis, J. W., Nabi, I. R., Demetriou, M. Metabolism, cell surface organization, and disease. Cell 139, 1229-1241, doi: 10.1016/j. cell.2009.12.008 (2009).
4. Marth, J. D., Grewal, P. K. Mammalian glycosylation in immunity. Nat Rev Immunol 8, 874-887, doi: 10.1038/nri2417 (2008).
5. Lebrilla, C. B., An, H. J. The prospects of glycan biomarkers for the diagnosis of diseases. Mol Biosyst 5, 17-20, doi: 10.1039/b811781k (2009).
6. Packer, N. H. et al. Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics 8, 8-20, doi: 10.1002/pmic.200700917 (2008).
7. Reis, C. A., Osorio, H., Silva, L., Gomes, C., David, L. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol 63, 322-329, doi: 10.1136/jcp.2009.071035 (2010).
8. Theodoratou, E. et al. The role of glycosylation in IBD. Nat Rev Gastroenterol Hepatol 11, 588-600, doi: 10.1038/nrgastro.2014.78 (2014).
9. Vanderschaeghe, D. et al. High-throughput profiling of the serum N-glycome on capillary electrophoresis microfluidics systems: toward clinical implementation of GlycoHepatoTest. Anal Chem 82, 7408-7415, doi: 10.1021/ac101560a (2010).
10. Wuhrer, M. Glycosylation profiling in clinical proteomics: heading for glycan biomarkers. Expert Rev Proteomics 4, 135-136, doi: 10.1586/14789450.4.2.135 (2007).
11. Ohtsubo, K., Marth, J. D. Glycosylation in cellular mechanisms of health and disease. Cell 126, 855-867, doi: 10.1016/j. cell.2006.08.019 (2006).
12. Pivac, N. et al. Human plasma glycome in attention-deficit hyperactivity disorder and autism spectrum disorders. Mol Cell Proteomics 10, M110 004200, doi: 10.1074/mcp.M110.004200 (2011).
13. Peracaula, R. et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 13, 457-470, doi: 10.1093/glycob/cwg041 (2003).
14. Sarrats, A. et al. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. OMICS 14, 465-474, doi: 10.1089/omi.2010.0050 (2010).
15. Miyoshi, E., Moriwaki, K., Nakagawa, T. Biological function of fucosylation in cancer biology. J Biochem 143, 725-729, doi: 10.1093/jb/mvn011 (2008).
16. Pierce, A. et al. Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients. Glycobiology 20, 1283-1288, doi: 10.1093/glycob/cwq090 (2010).
17. Anthony, R. M., Nimmerjahn, F. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant 16, 7-14, doi: 10.1097/MOT.0b013e328342538f (2011).
18. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8, 226-234, doi: 10.1038/nrd2804 (2009).
19. Marino, K., Bones, J., Kattla, J. J., Rudd, P. M. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 6, 713-723, doi: 10.1038/nchembio.437 (2010).
20. Lauc, G. et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLos Genet 9, e1003225, doi: 10.1371/journal.pgen.1003225 (2013).
21. Yang, L., Luo, Y., Wei, J. Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncol Rep 24, 571-577 (2010).
22. Pucic, M. et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 10, M111 010090, doi: 10.1074/mcp.M111.010090 (2011).
23. Vuckovic, F. et al. IgG Glycome in Colorectal Cancer. Clin Cancer Res, doi: 10.1158/1078-0432.ccr-15-1867 (2016).
24. Bakovic, M. P. et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res 12, 821-831, doi: 10.1021/pr300887z (2013).
25. Gui, J., Li, H. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics 21, 3001-3008, doi: 10.1093/bioinformatics/bti422 (2005).
26. Fuster, M. M., Esko, J. D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5, 526-542, doi: 10.1038/nrc1649 (2005).
27. Niu, N. et al. IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLos One 7, e47362, doi: 10.1371/journal.pone.0047362 (2012).
28. Kobata, A. The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles. Biochim Biophys Acta 1780, 472-478, doi: 10.1016/j.bbagen.2007.06.012 (2008).
29. Zhu, D., Ottensmeier, C. H., Du, M. Q., McCarthy, H., Stevenson, F. K. Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. Br J Haematol 120, 217-222 (2003).
30. Qian, Y. et al. Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. J Proteome Res 12, 4046-4055, doi: 10.1021/pr4003992 (2013).
31. Kanoh, Y. et al. Changes in serum IgG oligosaccharide chains with prostate cancer progression. Anticancer Res 24, 3135-3139 (2004).
32. Aurer, I. et al. Aberrant glycosylation of Igg heavy chain in multiple myeloma. Coll Antropol 31, 247-251 (2007).
33. Kodar, K., Stadlmann, J., Klaamas, K., Sergeyev, B., Kurtenkov, O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 29, 57-66, doi: 10.1007/s10719-011-9364-z (2012).
34. Bones, J. et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res 10, 1246-1265, doi: 10.1021/pr101036b (2011).
35. Alley, W. R. Jr. et al. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res 11, 2282-2300, doi: 10.1021/pr201070k (2012).
36. Gercel-Taylor, C., Bazzett, L. B., Taylor, D. D. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol 81, 71-76, doi: 10.1006/gyno.2000.6102 (2001).
37. Saldova, R. et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17, 1344-1356, doi: 10.1093/glycob/cwm100 (2007).
38. Vesely, M. D., Kershaw, M. H., Schreiber, R. D., Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29, 235-271, doi: 10.1146/annurev-immunol-031210-101324 (2011).
39. Gornik, O., Lauc, G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers 25, 267-278 (2008).
40. Gornik, O., Pavic, T., Lauc, G. Alternative glycosylation modulates function of IgG and other proteins-implications on evolution and disease. Biochim Biophys Acta 1820, 1318-1326, doi: 10.1016/j.bbagen.2011.12.004 (2012).
41. Thompson, S. J., Hitsumoto, Y., Zhang, Y. W., Rook, G. A., Elson, C. J. Agalactosyl IgG in pristane-induced arthritis. Pregnancy affects the incidence and severity of arthritis and the glycosylation status of IgG. Clin Exp Immunol 89, 434-438 (1992).
42. Fleming, S. C., Smith, S., Knowles, D., Skillen, A., Self, C. H. Increased sialylation of oligosaccharides on IgG paraproteins-a potential new tumour marker in multiple myeloma. J Clin Pathol 51, 825-830 (1998).
43. Vuckovic, F. et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol 67, 2978-2989, doi: 10.1002/art.39273 (2015).
44. Galar, M., Fernandez, A., Barrenechea, E., Bustince, H., Herrera, F. A review on ensembles for the class imbalance problem: bagging-, boosting-, and hybrid-based approaches. Systems, Man, and Cybernetics, Part C: Applications and Reviews. IEEE Transactions 42, 463-484 (2012).
45. Agakov, F. V., Orchard, P., Storkey, A. Discriminative Mixtures of Sparse Latent Fields for Risk Management. JMLR W&CP 22, 10-18 (2012).
46. Van Cutsem, E., Nordlinger, B., Cervantes, A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21 Suppl 5, v93-97, doi: 10.1093/annonc/mdq222 (2010).
47. Novokmet, M. et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep 4, 4347, doi: 10.1038/srep04347 (2014).
48. Theodoratou, E. et al. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 16, 684-693, doi: 10.1158/1055-9965.epi-06-0785 (2007).
49. Chambless, L. E., Diao, G. Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 25, 3474-3486, doi: 10.1002/sim.2299 (2006).
50. Friedman, J. Greedy function approximation: A gradient boosting machine. The Annals of Statistics 29, 1189-1232 (2001).
51. Ridgeway, G. The State of Boosting. Computing Science and Statistics 31, 172-181 (1999).
52. Looker, H. C. et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int 88, 888-896, doi: 10.1038/ki.2015.199 (2015).